Therapeutic Adoption

In the AI Story

The concept responds to the limitation of both the Luddite response and the triumphalist embrace. Refusal pretends one can stand outside the pharmacological condition that constitutes human existence as technical. Uncritical acceptance pretends the poison does not exist. Therapeutic adoption refuses both pretenses and installs itself in the difficulty of managing what cannot be separated.

Segal's practice provides concrete illustration. When he catches Claude's fabricated Deleuze reference and verifies against the source rather than accepting fluent output — that is therapeutic adoption. When he deletes an eloquent but hollow AI-generated passage and spends two hours writing by hand 'until I found the version of the argument that was mine, rougher, more qualified, more honest about what I didn't know' — that is therapeutic adoption. The act is costly in output terms but necessary for maintaining the practitioner's relationship to his own thought.

The practice requires institutional support. Individual therapeutic adoption cannot survive alone within institutions organized around the unconditional maximization of productive output. The factory owner's arithmetic — five people can do the work of a hundred — systematically pressures against the long circuits through which therapeutic capacity is maintained. Stiegler's contributory economy experiments attempted to build institutional structures supporting the practice at scale.

Therapeutic adoption is permanent practice, not a project with a completion date. The pharmakon does not stop producing its effects. The beaver does not build the dam once and walk away. The care is ongoing, never-finished work — which is why Stiegler linked it to the broader concept of care as the defining human practice in a technical world.

Origin

Stiegler developed therapeutic adoption across What Makes Life Worth Living: On Pharmacology (2010) and Taking Care of Youth and the Generations (2008).

The practical experiments at the Institut de Recherche et d'Innovation (IRI) and in the Plaine Commune contributory economy project provided institutional prototypes.

Key Ideas

Neither refusal nor embrace. Both are inadequate responses to the pharmacological condition; therapeutic adoption installs itself in the tension.

Practical wisdom, not rules. The practice resembles ancient metis — contextual judgment developed through engagement rather than principle application.

Permanent and never-finished. The pharmakon's effects do not cease; care must therefore be ongoing, not a completed project.

Requires institutional support. Individual therapeutic capacity cannot survive within institutions that systematically reward its opposite.

Debates & Critiques

Critics ask whether therapeutic adoption is meaningfully different from 'responsible use' rhetoric deployed by technology companies to deflect regulation. Defenders argue that the difference lies in the insistence that pharmacological care is a collective and political achievement, not a matter of individual consumer responsibility — and that the framework demands structural transformation rather than merely better individual choices.